Home LiteratureArticle Details
PMID: 845257 Published · ppublish English Comparative Study Journal Article

Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.

The Journal of clinical investigation ·Vol. 59 ·No. 4 ·1977-04-00 ·Pages 704-15

Sissons JG, Liebowitch J, Amos N, Peters DK

Abstract

The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated.

MeSH Terms
Adolescent Adult Complement C3/analysis,metabolism Complement C5/analysis,metabolism Complement System Proteins/metabolism Female Hepatitis/metabolism Humans Kidney Failure, Chronic/metabolism Lipodystrophy/metabolism Lupus Erythematosus, Systemic/metabolism Male Middle Aged Nephritis/metabolism
Chemicals
Complement C3 Complement C5 Complement System Proteins
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Sissons J G
Liebowitch J
Amos N
Peters D K
References (30)
30 references, click to expand
  1. ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.
    J Exp Med. 1965 Aug 1;122:277-98 PMID: 14316946
  2. The theory of tracer experiments with 131I-labelled plasma proteins.
    Phys Med Biol. 1957 Jul;2(1):36-53 PMID: 13484460
  3. Modulation of the alternative complement pathways by beta 1 H globulin.
    J Exp Med. 1976 Nov 2;144(5):1147-63 PMID: 62817
  4. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
    J Exp Med. 1976 Oct 1;144(4):1062-75 PMID: 62010
  5. Control of the amplification convertase of complement by the plasma protein beta1H.
    Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72 PMID: 1067618
  6. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
    J Exp Med. 1976 Oct 1;144(4):1076-93 PMID: 978134
  7. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
    J Exp Med. 1975 Oct 1;142(4):856-63 PMID: 1185108
  8. Skin lesions, angio-oedema, and hypocomplementaemia.
    Lancet. 1974 Dec 7;2(7893):1350-2 PMID: 4143312
  9. A method of trace iodination of proteins for immunologic studies.
    Int Arch Allergy Appl Immunol. 1966;29(2):185-9 PMID: 4160044
  10. Additional studies on human C5: development of a modified purification method and characterization of the purified product by polyacrylamide gel electrophoresis.
    Immunochemistry. 1972 Jul;9(7):709-23 PMID: 4261220
  11. Studies of serum complement in the hypocomplementaemic nephritides.
    Clin Exp Immunol. 1974 Nov;18(3):391-405 PMID: 4219908
  12. Complement studies in membrano-proliferative glomerulonephritis.
    Clin Exp Immunol. 1972 Jul;11(3):311-20 PMID: 4625395
  13. Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation.
    N Engl J Med. 1972 Oct 26;287(17):835-40 PMID: 4627271
  14. Analysis of disappearance time-curves after single injection of labelled proteins.
    Ciba Found Symp. 1972;9:113-30 PMID: 4573089
  15. Metabolism of radio-labelled C3: effects of in vivo activation in rabbits.
    Clin Exp Immunol. 1974 Mar;16(3):445-52 PMID: 4468849
  16. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.
    J Clin Invest. 1974 Jun;53(6):1578-87 PMID: 4830223
  17. Metabolism of the third component of complement (C3) in normal human subjects.
    Clin Sci Mol Med. 1974 Feb;46(2):223-9 PMID: 4817274
  18. Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus.
    Clin Exp Immunol. 1972 May;11(1):21-9 PMID: 5038771
  19. Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation.
    Immunochemistry. 1976 Apr;13(4):317-24 PMID: 820630
  20. Initiation of C3 cleavage in the alternative complement pathway.
    J Immunol. 1975 Nov;115(5):1357-61 PMID: 809512
  21. C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum.
    J Exp Med. 1975 Jul 1;142(1):139-50 PMID: 1097571
  22. Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator.
    Science. 1976 Sep 10;193(4257):1011-3 PMID: 948757
  23. C3 requirements for formation of alternative pathway C5 convertase.
    J Immunol. 1976 Aug;117(2):630-4 PMID: 950465
  24. The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro.
    Clin Exp Immunol. 1976 Jun;24(3):474-82 PMID: 939051
  25. The complement abnormalities of lipodystrophy.
    N Engl J Med. 1976 Feb 26;294(9):461-5 PMID: 1246331
  26. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
    J Immunol. 1976 Jan;116(1):1-7 PMID: 1245733
  27. Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF).
    J Immunol. 1976 Feb;116(2):568-70 PMID: 1249423
  28. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
    J Exp Med. 1975 Sep 1;142(3):760-72 PMID: 1165475
  29. Human C3 and C5: subunit structure and modifications by trypsin and C42-C423.
    J Immunol. 1975 Feb;114(2 pt 2):815-22 PMID: 1112981
  30. Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.
    J Clin Invest. 1967 Dec;46(12):2021-34 PMID: 6074005
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1977-04-00
Pages
704-15
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC372275
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]